Olaparib (brand name: Lynparza, Lipuzhuo; Beacon).

Description
Product introduction:
Olaparib produced by Beacon (also translated as Olaparib; generic name: Olaparib; brand names: Lynparza, Lipuzhuo) is a PARP (poly ADP-ribose polymerase) inhibitor. It blocks DNA repair enzymes, preventing cancer cells from repairing their DNA, which leads to cell death and helps delay or inhibit tumor progression. It has been approved by the FDA for the treatment of ovarian cancer, breast cancer, prostate cancer, and pancreatic cancer, and its potential in other tumors is also being explored, making it a promising broad-spectrum anticancer agent.

PARP refers to poly ADP-ribose polymerase. PARP inhibitors work by blocking DNA damage repair in tumor cells and promoting apoptosis, thereby enhancing the efficacy of radiotherapy and chemotherapy agents such as alkylating agents and platinum-based drugs.

Olaparib (Lynparza) was the first PARP inhibitor approved by the FDA for the treatment of recurrent ovarian cancer, receiving approval in December 2014. Clinical trials showed that it extended progression-free survival to 19.1 months and reduced the risk of disease progression or death by 65%, and it is effective regardless of BRCA1/2 mutation status. In 2017, the FDA expanded its indication to maintenance treatment for platinum-sensitive recurrent ovarian epithelial cancer. In 2018, it was further approved for BRCA-mutated HER2-negative metastatic breast cancer and maintenance treatment of platinum-sensitive recurrent ovarian cancer. Olaparib was launched in China in 2018 as the first PARP inhibitor available in the country. Later, it was also approved for metastatic pancreatic cancer and prostate cancer. In 2022 and 2023, it was included in China’s national reimbursement drug list, greatly improving accessibility. Overall, olaparib has significantly advanced the treatment of ovarian, breast, and prostate cancers.

Brand introduction:
Beacon Pharmaceuticals is a leading pharmaceutical company in Bangladesh, founded in 2001. It is the largest and most technologically advanced manufacturer of oncology and antiviral drugs in the country and one of the fastest-growing pharmaceutical companies in the region. Beacon Pharmaceuticals has obtained certifications including US FDA, UK MHRA GMP, and Australia TGA.

Indications:

1. Maintenance treatment of platinum-sensitive recurrent ovarian cancer, regardless of BRCA mutation status;
2. Treatment of BRCA-mutated HER2-negative metastatic breast cancer.

Dosage and administration:
(1) Ovarian cancer: recommended dose is 300 mg orally twice daily;
(2) Breast cancer: recommended dose is 300 mg orally twice daily;
(3) Continue treatment until disease progression or unacceptable toxicity;
(4) Dose interruption or reduction may be considered in case of adverse reactions.

Special populations:
Breastfeeding patients should discontinue either olaparib treatment or breastfeeding.

Common adverse reactions:
Anemia, nausea, fatigue, vomiting, diarrhea, dysgeusia, dyspepsia, decreased appetite, headache, myalgia, rash, etc.